Repligen (NASDAQ:RGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a research note issued to investors on Monday morning.

Several other brokerages have also commented on RGEN. HSBC assumed coverage on Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective for the company. Barclays lifted their target price on Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Jefferies Financial Group lowered their target price on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, September 12th. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Finally, Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.85.

Repligen Stock Down 2.0%

Repligen stock opened at $148.48 on Monday. The firm has a market cap of $8.35 billion, a price-to-earnings ratio of 7,427.71, a PEG ratio of 3.38 and a beta of 1.08. The stock has a fifty day simple moving average of $134.43 and a two-hundred day simple moving average of $128.63. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $188.80 million during the quarter, compared to analyst estimates of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The company’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several large investors have recently added to or reduced their stakes in RGEN. GAMMA Investing LLC increased its stake in Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 274 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Repligen by 60.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,822 shares of the biotechnology company’s stock worth $3,979,000 after acquiring an additional 11,193 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Repligen by 3.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 473,486 shares of the biotechnology company’s stock worth $60,843,000 after acquiring an additional 16,421 shares during the last quarter. KBC Group NV increased its stake in Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 329 shares during the last quarter. Finally, WCM Investment Management LLC increased its stake in Repligen by 6.1% during the first quarter. WCM Investment Management LLC now owns 102,992 shares of the biotechnology company’s stock worth $13,740,000 after acquiring an additional 5,906 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.